Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder.

Joyce VR, Oliva EM, Garcia CC, Trafton J, Asch SM, Wagner TH, Humphreys K, Owens DK, Bounthavong M. Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder. Addiction (Abingdon, England). 2023 Nov 1; 118(11):2203-2214.

Related HSR&D Project(s)

• RCS 17-154 – Career Scientist Award
• IIR 16-078 – Effectiveness of a Rescue Medication in Preventing Opioid Overdose in Veterans
• IIR 17-139 – Cost Effectiveness of Interventions to Reduce Morbidity from Opioid Dependency
• RCS 04-141 – Evaluating Treatment & Self-help Methods of Improving Functioning & Quality of Life Outcomes of Patients with Substance Abuse Disorders

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

AIMS: To compare healthcare costs and use between United States (US) Veterans Health Administration (VHA) patients with opioid use disorder (OUD) who experienced an opioid overdose (OD cohort) and patients with OUD who did not experience an opioid overdose (non-OD cohort). DESIGN: This is a retrospective cohort study of administrative and clinical data. SETTING: The largest integrated national health-care system is the US Veterans Health Administration''s healthcare systems. PARTICIPANTS: We included VHA patients diagnosed with OUD from October 1, 2017 through September 30, 2018. We identified the index date of overdose for patients who had an overdose. Our control group, which included patients with OUD who did not have an overdose, was randomly assigned an index date. A total of 66 513 patients with OUD were included for analysis (OD cohort: n = 1413; non-OD cohort: n = 65 100). MEASUREMENTS: Monthly adjusted healthcare-related costs and use in the year before and after the index date. We used generalized estimating equation models to compare patients with an opioid overdose and controls in a difference-in-differences framework. FINDINGS: Compared with the non-OD cohort, an opioid overdose was associated with an increase of $16?890 [95% confidence interval (CI)? = $15?611-18?169; P? < 0.001] in healthcare costs for an estimated $23.9 million in direct costs to VHA (95% CI? = $22.1 million, $25.7 million) within the 30?days following overdose after adjusting for baseline characteristics. Inpatient costs ($13?515; 95% CI? = $12?378-14?652; P? < 0.001) reflected most of this increase. Inpatient days (+6.15?days; 95% CI,? = 5.33-6.97; P? < 0.001), inpatient admissions (+1.01 admissions; 95% CI? = 0.93-1.10; P? < 0.001) and outpatient visits (+1.59 visits; 95% CI? = 1.34-1.84; P? < 0.001) also increased in the month after opioid overdose. Within the overdose cohort, healthcare costs and use remained higher in the year after overdose compared with pre-overdose trends. CONCLUSIONS: The US Veterans Health Administration patients with opioid use disorder (OUD) who have experienced an opioid overdose have increased healthcare costs and use that remain significantly higher in the month and continuing through the year after overdose than OUD patients who have not experienced an overdose.